Company intelligence / Profile preview

Neurobiological Technologies, Inc.

EmeryVille, California, United States

Ownership: Private
Development stage: Other

Overview

The company terminated development of its most advanced product candidate, Viprinex (ancrod), which was studied in Phase 3 clinical trials for evaluation as a new drug to treat acute ischemic stroke. The company operated under a plan of liquidation and dissolution approved by stockholders in October 2009.

Therapeutic areas: PsychiatryCardiovascularNeurology
Industry: Biotech

Drug pipeline

1 asset

ancrod

Partnerships

Celtic Pharmaceutical Holdings L.P.

Beyond the preview

Go deeper on Neurobiological Technologies, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neurobiological Technologies, Inc..